Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
ADHD is a neurodevelopmental disorder characterized by symptoms of inattention and / or
hyperactivity-impulsivity that affects nearly 6% of school-aged children and persists into
adulthood. More and more studies are interested in biomarkers of this pathology. The
oculomotricity, which allows to highlight deficits motor and attention present in ADHD, is
used routinely in the expert centers. In general, the pharmacological treatment of ADHD is
associated with a clinical response in approximately 70% of cases. Today, there is no review
to predict the individual response to treatment.
Hypotheses The investigators hypothesize that a precise analysis of the oculomotor markers
will allow to measure the improvement of the symptomatology of the ADHD disorder following
the introduction of the psycho-stimulatory treatment. In other words, the investigators
hypothesize that these markers could be a useful aid in patient follow-up by the clinician
and allow early identification of responder and non-responder patients.
Primary objective The main objective of this study is to measure the added value of
oculomotor examination in the follow-up of psycho-stimulant-treated ADHD patients.
Main Evaluation Criteria The primary endpoint is oculomotor performance. Parameters analyzed
for each saccade are latency, amplitude, duration, average speed, direction.
Secondary Criteria Evaluation (s) Correlations will be established between oculomotor data
and scores obtained at the clinical scales assessing ADHD symptoms of inattention and
hyperactivity as well as cognitive performance. The data obtained before the introduction of
the psycho-stimulant treatment (V0, baseline) will be compared with those obtained after
acute administration of methylphenidate (10 mg orally,V1) and during the follow-up visit at 6
months (V2).